amcasertib + capecitabine

**amcasertib + capecitabine** is a combination of two small molecule drugs with antineoplastic action. **Amcasertib (BBI503)** is a multi-kinase inhibitor that targets multiple serine/threonine kinases, including pathways regulating cancer stem cell signaling, prominently inhibiting Nanog and other factors associated with cancer stemness. It has shown preclinical cytotoxicity and apoptosis induction in breast cancer stem cells and may also affect invasion, migration, and epithelial-mesenchymal transition. **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), a cytotoxic antimetabolite that inhibits thymidylate synthase, thereby blocking DNA synthesis. Capecitabine is approved for use in metastatic breast cancer and has been combined with a range of anticancer agents. Their combination is being explored in clinical and preclinical studies for enhanced efficacy, particularly in breast cancer.